EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review

Kohei Tamura, Joji Kitayama iD, Yasushi Saga, Yuji Takei iD, Hiroyuki Fujiwara iD, Hironori Yamaguchi iD, Ryozo Nagai, Kenichi Aizawa

Pharmaceutics · 30.01.2026 · 18 (2) · 179

DOI: 10.3390/pharmaceutics18020179 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 30.01.2026. Verfasst von Kohei Tamura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Peritoneal metastases (PMs) remain difficult to treat because the peritoneum–plasma barrier limits drug penetration from the systemic circulation. Intraperitoneal chemotherapy (IPC), particularly repeated intraperitoneal (IP) administration via implantable ports, can achieve high local drug exposure with prolonged retention. This review summarizes the pharmacological rationale, clinical evidence, and future directions of catheter-based IPC, with emphasis on combined IP and systemic chemotherapy for ovarian, gastric, and pancreatic cancers.

Methods

We narratively reviewed prospective clinical trials and key retrospective studies evaluating IPC and compared repeated catheter-based IPC with hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC). Efficacy, safety, practice considerations, and opportunities for ascites-based monitoring were examined.

Results

In ovarian cancer, several randomized trials demonstrated improved progression-free survival (PFS), and in selected trials, improved overall survival (OS) was demonstrated using IP plus intravenous (IV) therapy, although in the latter trials, toxicity and catheter-related complications limited treatment completion. A phase III Intraperitoneal Therapy for Ovarian Cancer with Carboplatin (iPocc) trial further showed significantly prolonged PFS with IP carboplatin and weekly paclitaxel, with non-catheter-related toxicity comparable to that of IV therapy. In gastric and pancreatic cancer, phase II studies reported symptomatic control, cytologic conversion, and higher rates of conversion surgery in selected patients, although confirmatory phase III data are limited. Device complications, including infection, obstruction, and leakage, occurred, but were manageable.

Conclusions

Repeated catheter-based IPC is a feasible approach that enhances intraperitoneal drug delivery and complements IV chemotherapy. Future priorities include randomized trials, pharmacokinetic optimization, and biomarker-guided patient selection, supported by serial ascites assessment to refine indications and improve outcomes.

Schlagwörter

Stichwörter der Autor:innen

cancer treatmentchemotherapy deliveryclinical trialsdrug absorptionhyperthermic intraperitoneal chemotherapyintraperitoneal chemotherapyperitoneal metastasessystemic chemotherapytumor leukocyte ratiotumor microenvironment

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
  • Department of Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
  • Department of Translational Research, Clinical Research Center, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
  • Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
  • Clinical Pharmacology Center, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.

ORCID-Profile: Joji Kitayama, Yuji Takei, Hiroyuki Fujiwara, Hironori Yamaguchi

Zitieren

APA

Tamura, K., Kitayama, J., Saga, Y., Takei, Y., Fujiwara, H., Yamaguchi, H., Nagai, R., & Aizawa, K. (2026). Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review. Pharmaceutics, 18(2), 179. https://doi.org/10.3390/pharmaceutics18020179

Vancouver

Tamura K, Kitayama J, Saga Y, Takei Y, Fujiwara H, Yamaguchi H, et al. Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review. Pharmaceutics. 2026;18(2):179. doi:10.3390/pharmaceutics18020179

BibTeX
@article{Tamura2026,
  author = {Tamura, Kohei and Kitayama, Joji and Saga, Yasushi and Takei, Yuji and Fujiwara, Hiroyuki and Yamaguchi, Hironori and Nagai, Ryozo and Aizawa, Kenichi},
  title = {Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {179},
  doi = {10.3390/pharmaceutics18020179}
}
Kostenlos starten →